FSUE ‘Endopharm” obtained the Marketing Authorization for the medicine “Heparin, gel for external use, 1000 IU/g” (INN – sodium heparin), No. LP-007905.
“Heparin, gel for external use, 1000 IU/g” belongs to the pharmacotherapeutic group of direct-acting anticoagulant agents for topical application.
Sodium heparin is a direct-acting anticoagulant that belongs to the group of medium molecular weight heparins. It prevents thrombosis, inhibits the activity of hyaluronidase, activates the fibrinolytic properties of blood.
When applied externally, it has a local antithrombotic, anti-edematous and anti-inflammatory effect, improves blood microcirculation and activates tissue metabolism, as a result the processes of hematoma resorption are accelerated, the formation of blood clots is prevented, tissue swelling decreases.
“Heparin, gel for external use, 1000 IU / g” can be used for the following indications:
• superficial vein diseases: varicose veins, chronic venous insufficiency and related complications (thrombophlebitis, periphlebitis);
• blunt injuries and bruises of soft tissues;
• subcutaneous hematomas, including hematomas after operations on the veins, phlebectomy;
• localized infiltrates and soft tissue swelling.
The shelf life of the medicine is 3 years.
Comment type is not specified in the component properties.